CD33 and acute myeloid leukemia: For example, dual targeting of AML cells has been pursued with a CD33 × CD16a × CD123 TsAb, which induced significantly stronger NK lysis of primary leukemic cells than the BsAb version, although the optimized candidate SPM-2 did not reach clinical trials [121].